Risk of Esophageal and Gastric Cancer by Histologic Subtype in Steatotic Liver Disease: A UK Biobank Study
Open Access
Abstract
Aim: The recently updated steatotic liver disease (SLD) nomenclature provides a refined classification accounting for both metabolic dysfunction and alcohol exposure. However, the relationship between SLD subtypes and upper gastrointestinal (UGI) cancer risk remains unclear. Methods: We analyzed 456,367 UK Biobank participants, categorizing them into non-SLD, metabolic dysfunction-associated steatotic liver disease with no alcohol (MASLD1), MASLD with minimal alcohol use (MASLD2), metabolic dysfunction-associated alcohol-related liver disease (MetALD), and alcohol-associated liver disease (ALD) groups. Cox proportional hazards models estimated cancer risks over a median 13-year follow-up, with histologic subtype-specific analyses. Results: Compared to non-SLD, esophageal cancer risk was significantly elevated in all SLD groups with any alcohol consumption (MASLD2, MetALD, and ALD), but not in purely metabolic SLD without alcohol (MASLD1). This association was driven by adenocarcinoma subtype, with hazard ratios ranging from 1.67 to 1.80 in alcohol-exposed SLD groups. For gastric cancer, elevated risk was observed primarily in ALD and MetALD groups, affecting intestinal-type cancers. Squamous cell esophageal cancer and non-intestinal gastric cancer showed no significant associations. Conclusions: Upper GI cancer risk in SLD patients is significantly modified by alcohol consumption, with combined metabolic dysfunction and alcohol exposure conferring the highest risks for esophageal adenocarcinoma and intestinal-type gastric cancer. Clinically, these findings suggest that SLD patients with any level of alcohol consumption require heightened cancer surveillance. Even minimal alcohol intake substantially increases cancer risk in metabolically compromised individuals, supporting alcohol reduction as a key preventive strategy.Keywords
Funding Information
- Catholic Medical Center Research Foundation
This publication has 33 references indexed in Scilit:
- Metabolic Dysfunction–Associated Steatotic Liver DiseaseNew England Journal of Medicine, 2025
- Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver DiseaseJAMA Internal Medicine, 2025
- Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021The Lancet, 2025
- Differential risk of 23 site‐specific incident cancers and cancer‐related mortality among patients with metabolic dysfunction‐associated fatty liver disease: a population‐based cohort study with 9.7 million Korean subjectsCancer Communications, 2023
- Dissecting the genetic heterogeneity of gastric cancerEBioMedicine, 2023
- Risk of nonalcoholic fatty liver disease and associations with gastrointestinal cancersHepatology Communications, 2022
- Helicobacter pylori infection, chronic atrophic gastritis and risk of stomach and esophagus cancer: Results from the prospective population‐based ESTHER cohort studyInternational Journal of Cancer, 2019
- Key role of local acetaldehyde in upper GI tract carcinogenesisBest Practice & Research Clinical Gastroenterology, 2017
- Dissolution of lipids from mucus: A possible mechanism for prompt disruption of gut barrier function by alcoholToxicology Letters, 2015
- Esophageal CarcinomaNew England Journal of Medicine, 2014